• Deuterated Tetrazole CYP51 Inhibitor V23: Study Insights

  2026-09-02

  The 2025 European Journal of Medicinal Chemistry study describes V23, a deuterated tetrazole CYP51 inhibitor developed to improve antifungal breadth, resistance activity, human CYP selectivity, and metabolic stability. Its combined biochemical, microbiological, cellular, and in vivo data position V23 as a promising lead for invasive fungal infection research, while also highlighting the challenges of translating early pharmacodynamic findings into clinical development.

• Deferiprone for Iron-Stress Metabolism Studies

  2026-09-01

  Deferiprone enables controlled iron depletion without relying on DMSO or ethanol, making it useful for enterocyte metabolism, cancer biology, oxidative stress, and apoptosis studies. This guide translates recent IPEC-J2 findings into practical assay designs, controls, optimization steps, and troubleshooting strategies.

• Azilsartan Medoxomil: Assay Design Guide

  2026-09-01

  Azilsartan medoxomil monopotassium is a powerful tool for connecting sustained AT1 receptor antagonism with experimental blood pressure endpoints. This guide translates TAK 491 pharmacology and 2024 network meta-analysis evidence into practical assay and protocol decisions.

• Nigericin Sodium Salt: Protocol and QC Guide

  2026-08-31

  Nigericin sodium salt is a potassium ionophore for controlled K+/H+ exchange, membrane ion-gradient perturbation, and cytoplasmic pH studies. This dossier-led guide covers preparation, short-exposure workflows, platelet and lead-ion assay controls, and limitations; it is for research use only and not for diagnostic or therapeutic applications.

• Demethyleneberberine in Neurodegenerative Disorders

  2026-08-31

  The 2022 Molecular Biology Reports review proposes Demethyleneberberine (DMB), a berberine metabolite, as a neuroprotective candidate acting across neuroinflammation, oxidative stress, mitochondrial dysfunction, and cellular energy regulation. Its main contribution is a testable mechanistic framework centered on NF-κB, MAPK, and AMPK signaling, while also clarifying that most evidence remains preclinical and indirect.

• PD 0332991: CDK4/6 Assay Workflows

  2026-08-30

  Build reproducible Rb-centered cell-cycle assays with PD 0332991 (Palbociclib) HCl, from dose preparation through flow-cytometry validation. The workflow also shows how to use CDK4/6 inhibition as a controlled cell-state variable when interpreting DNA-repair phenotypes in lung cancer models.

• Temafloxacin Activity Against Gram-Negative Bacteria

  2026-08-29

  Dwight J. Hardy’s review organized the in vitro activity of temafloxacin against respiratory, enteric, sexually transmitted, and other Gram-negative pathogens in direct comparison with ciprofloxacin and ofloxacin. Its main practical contribution is a species- and assay-specific interpretation of MIC data, including the important finding that temafloxacin was substantially less active than ciprofloxacin against Pseudomonas aeruginosa.

• DON Liver Injury: Mitophagy and Nrf2 Disruption

  2026-08-28

  The reference study proposes that deoxynivalenol-induced hepatotoxicity reflects a coupled mechanism: overactivated PINK1/Parkin-mediated mitophagy damages mitochondrial homeostasis while suppression of the p62–Keap1–Nrf2 pathway weakens antioxidant defense. Mouse and AML-12 cell experiments, together with Mdivi-1, si-PINK1, and p62-overexpression interventions, provide a mechanistic framework for interpreting oxidative stress, inflammation, apoptosis, and lipid-metabolism abnormalities after DON exposure.

• From STING Structure to Smarter Oncology Screens

  2026-08-28

  Structural insight into STING activation shows why translational oncology screens should connect phenotype, pathway engagement, and molecular mechanism. This article explains how DiscoveryProbe™ Anti-cancer Compound Library (SKU: L1023) can support that evidence chain across oncogenic signaling, immune biology, and drug-discovery strategy.

• EZ Cap™ OVA mRNA for Immune Assays

  2026-08-27

  EZ Cap™ OVA mRNA provides a defined Ovalbumin mRNA payload for comparing transfection systems, protein expression enhancement, and inflammatory readouts. Its Cap 1 structure, poly(A) tail, and controlled formulation make it especially useful for immune response immunogen studies, delivery benchmarking, and vaccine development research.

• Nile Red Workflow for Laryngeal Cancer Lipids

  2026-08-27

  Nile Red enables a two-channel view of intracellular lipid storage: green fluorescence favors lipid droplets, while red fluorescence captures droplets plus membrane context. This workflow translates lipid-metabolism signals from laryngeal cancer research into practical imaging, controls, and troubleshooting steps without treating fluorescence as a stand-alone prognostic readout.

• Cistanche Nanovesicles Protect Sertoli Cells

  2026-08-26

  This reference study identifies Cistanche deserticola exosome-like nanovesicles as a plant-derived intervention for cyclophosphamide-induced testicular injury. Its central mechanistic finding is that vesicle-delivered miR159b-3p suppresses P21, restores CDK1 activation, and alleviates cell-cycle arrest in Sertoli cells, while human non-obstructive azoospermia data support the relevance of the pathway.

• Toremifene for Breast Cancer: 20 Years of Evidence

  2026-08-26

  This review synthesizes two decades of clinical experience with toremifene, emphasizing its efficacy, safety, pharmacokinetics, and role as an alternative endocrine therapy for postmenopausal patients with hormone-sensitive breast cancer. Its main contribution is a balanced clinical framework: toremifene is supported as an effective option, but the available evidence does not establish a definitive safety advantage over tamoxifen.

• PRC2 Inhibition Enables Chimpanzee Naive PSCs

  2026-08-25

  Huang et al. show that excessive PRC2-mediated H3K27me3 deposition blocks the self-renewal of chimpanzee naive pluripotent stem cells. Pharmacological and genetic disruption of PRC2 produced blastoid-competent cells and also improved feeder-free propagation of human naive PSCs, establishing chromatin repression as a central barrier to comparative primate pluripotency studies.

• DFO Fingerprint Detection: Chemistry Beyond Workflow

  2026-08-25

  DFO (9H-1,8-Diazafluoren-9-one) is more than a fluorescent fingerprint reagent: its amino acid reactivity creates a chemically informative readout on porous evidence. This article examines assay design, matrix effects, validation strategy, and lessons from modern mechanistic research.

8037 records 1/536 page Next 12345 下5页 Last page